Bolags- och kapitalmarknadsjurist till Vator Securities
Som bolags- och kapitalmarknadsjurist kommer du att arbeta med ECM-transaktioner där Vator Securities agerar finansiell rådgivare.
Din roll kommer vara att tillsammans med teamet inom Corporate Finance och ECM utarbeta optimala lösningar för en transaktion. Du kommer även att vara primär kontaktpunkt mot de externa legala rådgivarna i respektive transaktion.
Read More
Vator Securities rådger Xintela i 37 MSEK optionsinlösen
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 37 miljoner.
Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.
Read More
Vator Securities advises NextCell Pharma on 150 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million.
NextCell is a cell therapy company that has recently finished phase II with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes. In the Company’s clinical trials, ProTrans™ has demonstrated both safety and efficacy regarding the patient’s own preservation of insulin production.
Read More
Vator Securities advises Scandion Oncology on 236 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 236 million.
Scandion Oncology is a clinical phase II biotechnology company addressing cancer drug resistance as a complement to existing anti-cancer therapies by developing first-in-class, oral add-on drugs. Used as a combination therapy, the Company’s products have the potential to quickly reach peak sales in addition to potentially offering better response rates and increased survival time with improved quality of life.
Read More
Vator Securities advises Moberg Pharma on 150 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million.
Moberg Pharma is a Specialty Pharma company focused on developing and commercialising proprietary, acquired and licensed products globally, from clinical development of products based on proven substances to commercialisation.
Read More
Vator Securities advises A3P Biomedical on 110 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 110 million.
The SEK 110 million in growth capital was raised from institutional and private investors in Sweden to fund the commercialization of Stockholm3, A3P’s superior prostate cancer test.
Read More
Vator Securities advises SciBase on 32 MSEK Warrants
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 32 million.
SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma.
Read More
Vator Securities advises Fundler on 17 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 17 million.
Fundler is the first hybrid robo-advisor in the Nordics. The company’s unique savings offering combines automated investment advice and personal financial advisers
Read More